Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to DeclineZacks Investment Research • 10/22/26
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026GlobeNewsWire • 10/19/26
Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse TakeoverSeeking Alpha • 10/16/26
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPNBusiness Wire • 09/24/26
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHDGlobeNewsWire • 08/31/26
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its ShareholdersBusiness Wire • 08/29/26
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?Zacks Investment Research • 08/24/26
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026Zacks Investment Research • 08/21/26
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 OutlookZacks Investment Research • 08/04/26
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)PRNewsWire • 08/03/26
Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public ShareholdersPRNewsWire • 08/03/26
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in RevenueBenzinga • 08/03/26
Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/03/26